Targeted Strategies for Today's Evolving Markets

MissionIR Blog

ImmunoCellular Therapeutics, Ltd. (IMUC) Starts Presentation at 2nd Annual Marcum MicroCap Conference

Posted on May 30, 2013 by MissionIR

ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. IMUC is conducting a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. For more information visit the company’s Web site at www.IMUC.com

Let us hear your thoughts below:

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *